About Us

Learn about who we are, what we believe
and the people who lead us

Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission Our Leadership Our experienced leaders are bound by passion and science Our Values We live our values of commitment, empowerment and teamwork Our Responsibility Advancing a vision for change Medical Affairs We are committed to advancing science and medicine through awareness, education and research

Our Focus

Discover our unique scientific approach
for diseases with high unmet need.

Demodex Blepharitis Highly prevalent and damaging eyelid disease Lyme Disease A growing public health crisis with no approved solution Ocular Rosacea A common inflammatory condition of the eyelid and eyelid margin

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

XDEMVY® (lotilaner ophthalmic solution) 0.25% Available to prescribe today

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs

Pipeline Overview A commitment to pursuing the root cause of disease TP-04 An investigational treatment for ocular rosacea TP-05 An investigational therapy for the prevention of Lyme disease

Investors & News

Find additional corporate
and stock information.

Investors Overview

News & Presentations

Publications Corporate Governance

Stock Information

Other Resources

Our Story Our Leadership Our Values Our Responsibility Medical Affairs

Demodex Blepharitis Lyme Disease Ocular Rosacea

XDEMVY® (lotilaner ophthalmic solution) 0.25%

Pipeline Overview TP-04 TP-05

Careers

Financials

SEC Filings

Filing date	Form	Description	View
Aug 25, 2026	144	Filed by "insiders" prior intended sale of restricted stock.	0001959173-26-006443.pdf 0001959173-26-006443.rtf View HTML
Aug 19, 2026	144	Filed by "insiders" prior intended sale of restricted stock.	0001959173-26-006221.pdf 0001959173-26-006221.rtf View HTML
Aug 13, 2026	SCHEDULE 13G/A	SCHEDULE 13G/A - Description	0001274173-26-000207.pdf 0001274173-26-000207.rtf 0001274173-26-000207.xls View HTML
Aug 6, 2026	8-K	Report of unscheduled material events or corporate event	0001819790-26-000060.pdf 0001819790-26-000060.rtf 0001819790-26-000060.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Aug 6, 2026	8-K	Report of unscheduled material events or corporate event	0001819790-26-000062.pdf 0001819790-26-000062.rtf 0001819790-26-000062.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Aug 6, 2026	8-K	Report of unscheduled material events or corporate event	0001819790-26-000063.pdf 0001819790-26-000063.rtf 0001819790-26-000063.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Aug 6, 2026	10-Q	Quarterly report which provides a continuing view of a company's financial position	0001819790-26-000064.pdf 0001819790-26-000064.rtf 0001819790-26-000064.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Jul 13, 2026	8-K	Report of unscheduled material events or corporate event	0001819790-26-000048.pdf 0001819790-26-000048.rtf 0001819790-26-000048.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Jul 8, 2026	8-K	Report of unscheduled material events or corporate event	0001819790-26-000046.pdf 0001819790-26-000046.rtf 0001819790-26-000046.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Jun 29, 2026	8-K	Report of unscheduled material events or corporate event	0001819790-26-000043.pdf 0001819790-26-000043.rtf 0001819790-26-000043.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Anchor Link for Quarterly Results

Data provided by Kaleidoscope.